Consequently, while some regimens, such as RAAS + SGLT2 inhibitors, have evidence of benefit in CKD with different causes (which included hypertension), combinations with GLP-1RAs or DPP-4 inhibitors need to be evaluated further in hypertensive CKD. Here, SLC5A2 is linked to chronic kidney disease.